Publications by authors named "Nicola Bianchetti"
Article Synopsis
- Mantle cell lymphoma (MCL) is a severe form of non-Hodgkin lymphoma with a generally poor outcome, and the effectiveness of PET/CT scans in assessing treatment response in these patients is still uncertain.
- A study analyzed data from 120 MCL patients, focusing on various PET/CT parameters to determine their impact on progression-free survival (PFS) and overall survival (OS) following treatment.
- The findings showed that metabolic response and tumor burden parameters (like metabolic tumor volume and total lesion glycolysis) are key predictors of PFS, while features related to tumor spread are important for estimating OS.
Here we report two cases of myeloma patients who became positive for SARS-CoV-2 infection during the acute phase of autologous stem cell transplant. Both patients were promptly treated with monoclonal antibodies and remdesivir, and, despite the profound neutropenia and lymphopenia, they did not develop respiratory failure and they remained paucisymptomatic during the entire period of aplasia. Neutrophil engraftment took place as expected and the patients were discharged quickly and did not experience adverse effects after discharge.
View Article and Find Full Text PDFThe prognosis of acute myeloid leukemia depends on genetic aberrations, particularly NPM1 and FLT3-ITD mutations. The targeted drugs’ availability has renewed interest in FLT3 mutations, but the impact of these genetic alterations using these treatments is yet to be confirmed. Our objective was to evaluate the results obtained with the intensified NILG-AML 01/00 protocol (ClinicalTrials.
View Article and Find Full Text PDFThe role of allogeneic stem cell transplantation (allo-SCT) in mantle cell lymphoma (MCL) is uncertain, even more in the era of bruton's tyrosine kinase inhibitors (BTKi) and chimeric antigen receptor T-cells. We retrospectively analyzed 55 patients who underwent allo-SCT for MCL relapsed or refractory (r/r) after rituximab and high-dose cytarabine within the MANTLE-FIRST project. With a median follow-up of 3.
View Article and Find Full Text PDFEvans syndrome (ES) is a rare condition, defined as the presence of 2 autoimmune cytopenias, most frequently autoimmune hemolytic anemia and immune thrombocytopenia (ITP) and rarely autoimmune neutropenia. ES can be classified as primary or secondary to various conditions, including lymphoproliferative disorders, other systemic autoimmune diseases, and primary immunodeficiencies, particularly in children. In adult ES, little is known about clinical features, disease associations, and outcomes.
View Article and Find Full Text PDFBackground: Patients with cancer are considered highly vulnerable to the recent coronavirus disease 2019 (COVID-19) pandemic. However, there are still few data on COVID-19 occurring in hematologic patients.
Methods: One hundred two patients with COVID-19 symptoms and a nasopharyngeal swab positive for severe acute respiratory syndrome coronavirus 2 seen at 2 hematologic departments located in Lombardy, Italy, during March 2020 were studied.
Article Synopsis
- Autologous stem cell transplantation (ASCT) shows promise for older patients (ages 65-75) with Multiple Myeloma, but clear eligibility criteria are lacking.
- A study of 131 patients found that those deemed "frail" were not eligible for ASCT and had significantly worse progression-free survival (PFS) compared to fit and unfit patients.
- The IMWG frailty score may help identify unfit patients aged 70-75, as these patients had outcomes with ASCT that were similar to those receiving less intensive treatments, highlighting the need for better patient selection.
translocations, a hallmark of Burkitt lymphoma, occur in 5-15% of diffuse large B-cell lymphoma, and have a negative prognostic impact. Numerical aberrations of have also been detected in these patients, but their incidence and prognostic role are still controversial. We analyzed the clinical impact of increased copy number on 385 patients with diffuse large B-cell lymphoma screened at diagnosis for , , and rearrangements.
View Article and Find Full Text PDFObjective: Mantle cell lymphoma (MCL) is an aggressive lymphoma sub-type with poor prognosis and high 18F-FDG avidity at PET/CT; nowadays, no validated criteria for PET/CT in treatment response evaluation and prediction of outcome are present. The aim of study was to investigate whether the metabolic PET/CT features may predict treatment evaluation and prognosis in MCL.
Methods: We retrospectively enrolled 87 patients who underwent baseline 18F-FDG PET/CT and 85 end-of-treatment (eot) PET/CT.